Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.65 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.60 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | CYP19A1 known ✓ | P11511 | 3/20 | 0.46 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | NAAA | Q02083 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30109432 | 1.00 | HRH1 (0.65) | HRH1KCNH2LMNAALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL19134095 | 1.00 | HRH1 (0.65) | HRH1KCNH2LMNAALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29595625 | 1.00 | HRH1 (0.65) | HRH1KCNH2LMNAALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11119743 | 1.00 | HRH1 (0.65) | HRH1KCNH2LMNAALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1348933 | 1.00 | HRH1 (0.65) | HRH1KCNH2LMNAALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11554457 | 1.00 | HRH1 (0.65) | HRH1KCNH2LMNAALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28349232 | 1.00 | HRH1 (0.65) | HRH1KCNH2LMNAALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9482465 | 1.00 | HRH1 (0.65) | HRH1KCNH2LMNAALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL259074 | 1.00 | HRH1 (0.65) | HRH1KCNH2LMNAALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL22264600 | 1.00 | HRH1 (0.65) | HRH1KCNH2LMNAALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719374-A1 | TREATMENT REGIMENS FOR EARLY IDIOPATHIC PARKINSON'S DISEASE | Bial-Portela & CA, S.A. (PT) | 2026-04-08 | — | — | EP | disclosed |
| US-20260053782-A1 | TREATMENT REGIMENS FOR PARKINSON'S DISEASE | BIAL PORTELA & CA SA (PT) | 2026-02-26 | — | — | US | disclosed |
| US-12458578-B2 | Composition for inhibiting plaque formation | SUNSTAR SUISSE SA (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250275934-A1 | MEDICAMENTS FOR SLOWING PARKINSON'S DISEASE | BIAL - PORTELA & CA, S.A. (PT) | 2025-09-04 | — | — | US | disclosed |
| US-20250223270-A1 | Sulfonamide Compounds and Use Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-07-10 | — | — | US | disclosed |
| US-12344588-B2 | Sulfonamide compounds and use thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-07-01 | — | — | US | disclosed |
| EP-4572751-A1 | TREATMENT REGIMENS FOR PARKINSON'S DISEASE | BIAL - Portela & Ca., S.A. (PT) | 2025-06-25 | — | — | EP | disclosed |
| CN-119701005-A | Oral solution containing epicapone inclusion compound and preparation method thereof | 南京科默生物医药有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119174763-A | Composition for inhibiting plaque formation | 盛势达（瑞士）有限公司 | 2024-12-24 | — | — | CN | disclosed |
| WO-2024242579-A1 | TREATMENT REGIMENS FOR EARLY IDIOPATHIC PARKINSON'S DISEASE | BIAL-PORTELA & CA., S.A. (PT) | 2024-11-28 | — | — | WO | disclosed |
| US-12097193-B2 | Methods for the administration of COMT inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2024-09-24 | — | — | US | disclosed |
| WO-2024039256-A1 | TREATMENT REGIMENS FOR PARKINSON'S DISEASE | BIAL - PORTELA & CA, S.A. (PT) | 2024-02-22 | — | — | WO | disclosed |
| US-20240000762-A1 | TREATMENT REGIMENS FOR EARLY IDIOPATHIC PARKINSON'S DISEASE | BIAL - PORTELA & CA, S.A. (PT) | 2024-01-04 | — | — | US | disclosed |
| US-20230390267-A1 | TREATMENT REGIMENS FOR EARLY IDIOPATHIC PARKINSON'S DISEASE | BIAL - PORTELA & CA, S.A. (PT) | 2023-12-07 | — | — | US | disclosed |
| US-20230372220-A1 | COMPOSITION FOR INHIBITING PLAQUE FORMATION | SUNSTAR SUISSE SA (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230355560-A1 | MEDICAMENTS FOR SLOWING PARKINSON'S DISEASE | BIAL - PORTELA & CA, S.A. (PT) | 2023-11-09 | — | — | US | disclosed |
| EP-4223287-A1 | COMPOSITION FOR INHIBITING PLAQUE FORMATION | Sunstar Suisse SA (CH) | 2023-08-09 | — | — | EP | disclosed |
| CN-116249527-A | Composition for inhibiting plaque formation | 盛势达（瑞士）有限公司 | 2023-06-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12458578-B2 | Composition for inhibiting plaque formation | CAPG, CETP, APOB | HRH1 3523/4885KCNH2 409/4885HRH3 1934/4885 |
| US-20230372220-A1 | COMPOSITION FOR INHIBITING PLAQUE FORMATION | CAPG, CETP, APOB | HRH1 3523/4885KCNH2 409/4885HRH3 1934/4885 |
| US-20260053782-A1 | TREATMENT REGIMENS FOR PARKINSON'S DISEASE | COMT, DDC, DDT | HRH1 1503/4885KCNH2 3115/4885HRH3 1926/4885 |
| US-20250223270-A1 | Sulfonamide Compounds and Use Thereof | STS, SULT2A1, TPST2 | HRH1 2658/4885KCNH2 2899/4885HRH3 2789/4885 |
| US-12344588-B2 | Sulfonamide compounds and use thereof | STS, SULT2A1, TPST2 | HRH1 2658/4885KCNH2 2899/4885HRH3 2789/4885 |
| US-12097193-B2 | Methods for the administration of COMT inhibitors | COMT, OPRK1, OPRM1 | HRH1 1952/4885KCNH2 1707/4885HRH3 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.